Profit/loss of Ablynx 2013-2017
This statistic illustrates the profit/loss of Ablynx from 2013 to 2017. Ablynx is a Belgian biopharmaceutical company engaged in the discovery and the development of nanobodies. In 2018, the French pharmaceutical company Sanofi acquired Ablynx for 3.9 billion euros. As of 2017, the loss of Ablynx amounted to roughly 108 million euros, which is more than in the previous year, when Ablynx had a loss of approximately one million euros.
